New adjuvant therapy for colon cancer: Justified hope or commercial hype

E. Galanis; S. R. Alberts; M. J. O'Connell

doi:10.1016/s1055-3207(18)30120-0

New adjuvant therapy for colon cancer: Justified hope or commercial hype

E. Galanis, S. R. Alberts, M. J. O'Connell

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

This article discusses the role of adjuvant chemotherapy for colon cancer. Six months of adjuvant 5-FU/leucovorin represent the standard of care for resected stage III colon cancer patients. The role of adjuvant chemotherapy for stage II patients remains controversial. Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches.

Original language	English (US)
Pages (from-to)	813-823
Number of pages	11
Journal	Surgical Oncology Clinics of North America
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/s1055-3207(18)30120-0
State	Published - 2000

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/s1055-3207(18)30120-0

Cite this

@article{3c0cb47ba4e7411a896622c13ec01972,

title = "New adjuvant therapy for colon cancer: Justified hope or commercial hype",

abstract = "This article discusses the role of adjuvant chemotherapy for colon cancer. Six months of adjuvant 5-FU/leucovorin represent the standard of care for resected stage III colon cancer patients. The role of adjuvant chemotherapy for stage II patients remains controversial. Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches.",

author = "E. Galanis and Alberts, {S. R.} and O'Connell, {M. J.}",

year = "2000",

doi = "10.1016/s1055-3207(18)30120-0",

language = "English (US)",

volume = "9",

pages = "813--823",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - New adjuvant therapy for colon cancer

T2 - Justified hope or commercial hype

AU - Galanis, E.

AU - Alberts, S. R.

AU - O'Connell, M. J.

PY - 2000

Y1 - 2000

N2 - This article discusses the role of adjuvant chemotherapy for colon cancer. Six months of adjuvant 5-FU/leucovorin represent the standard of care for resected stage III colon cancer patients. The role of adjuvant chemotherapy for stage II patients remains controversial. Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches.

AB - This article discusses the role of adjuvant chemotherapy for colon cancer. Six months of adjuvant 5-FU/leucovorin represent the standard of care for resected stage III colon cancer patients. The role of adjuvant chemotherapy for stage II patients remains controversial. Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=0033809295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033809295&partnerID=8YFLogxK

U2 - 10.1016/s1055-3207(18)30120-0

DO - 10.1016/s1055-3207(18)30120-0

M3 - Review article

C2 - 11008249

AN - SCOPUS:0033809295

SN - 1055-3207

VL - 9

SP - 813

EP - 823

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 4

ER -

New adjuvant therapy for colon cancer: Justified hope or commercial hype

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this